Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Cancer Immunol Res. 2016 Dec 21;5(1):17–28. doi: 10.1158/2326-6066.CIR-16-0206

Fig. 6.

Fig. 6

Immune checkpoint therapy elicited antibody responses to ANGPT2. A and B, ANGPT2 antibodies were detected in pre- and posttreatment plasma samples of ipilimumab plus bevacizumab-treated patients by immunoblot analysis (A) and ELISA (B). Clinical responses are also indicated. C, Proportions of patients receiving ipilimumab plus bevacizumab (n =43), ipilimumab (n = 36), and PD-1 blockade (n = 38) displayed an increase by 40% or more in ANGPT2 antibody concentrations. D–F, Longitudinal analysis of serum ANGPT2 and/or ANGPT2 antibodies in patients receiving ipilimumab plus bevacizumab (D), ipilimumab (E), or PD-1 blockade (F). Dosing of ipilimumab, bevacizumab, or nivolumab was indicated on the x-axis. Day 0 is pretreatment.